SCHEMBL3058717

SCHEMBL3058717

Cc1cc(NCc2ccc(F)cc2)c2ccccc2n1

nearest known ligand 0.79

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.67
KMT2A Q03164 3/20 0.67
GPR35 Q9HC97 1/20 0.67
CYP2C19 P33261 1/20 0.57
ALDH1A1 P00352 1/20 0.56
NCF1 P14598 3/20 0.56
LMNA P02545 1/20 0.54
MAPT P10636 1/20 0.54
APP P05067 1/20 0.54
NTRK1 P04629 1/20 0.53
ACP1 P24666 2/20 0.52
OPRK1 P41145 1/20 0.51
CD38 P28907 1/20 0.51
HTT P42858 2/20 0.50
SMN1; SMN2 Q16637 2/20 0.50
GALR3 O60755 1/20 0.50
RAB9A P51151 1/20 0.50
PKM P14618 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3058825 0.90 CYP2C19 (0.64) MEN1KMT2AGPR35CYP2C19ALDH1A1
SCHEMBL3056723 0.86 ACP1 (0.62) MEN1KMT2AGPR35CYP2C19NCF1
SCHEMBL3059015 0.81 CD38 (0.61) MEN1KMT2AGPR35CYP2C19NCF1
SCHEMBL9363750 0.77 MEN1 (0.61) MEN1KMT2AGPR35CYP2C19NCF1
SCHEMBL3058636 0.77 CD38 (0.56) CYP2C19ACP1OPRK1CD38HTT
SCHEMBL3054345 0.76 CD38 (0.53) MEN1KMT2ACYP2C19ACP1OPRK1
Hydrochloric Acid SCHEMBL9494706 0.76 CD38 (0.55) CYP2C19ACP1OPRK1CD38HTT
SCHEMBL15673549 0.75 HDAC6 (0.64) MEN1KMT2ALMNAMAPTAPP
SCHEMBL7500041 0.75 CYP2C19 (0.69) MEN1KMT2ACYP2C19ALDH1A1NCF1
SCHEMBL6617289 0.75 MEN1 (0.59) MEN1KMT2AGPR35CYP2C19ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210161810-A1 Pharmaceutical Compositions Including Low Dosages of Desmopressin FIRST GENERATION CAPITAL INC. (CA) 2021-06-03 US disclosed
US-9504647-B2 Pharmaceutical formulations of desmopressin FERRING B.V. (NL) 2016-11-29 US disclosed
US-20160175246-A1 PHARMACEUTICAL FORMULATIONS FERRING B.V. (NL) 2016-06-23 US disclosed
US-8420670-B2 4-benzylaminoquinolines, pharmaceutical compositions containing them, and their use in therapy ABBOTT LABORATORIES (US) 2013-04-16 US disclosed
US-8420670-B2 4-benzylaminoquinolines, pharmaceutical compositions containing them, and their use in therapy ABBOTT LABORATORIES (US) 2013-04-16 US disclosed
US-8420670-B2 4-benzylaminoquinolines, pharmaceutical compositions containing them, and their use in therapy ABBOTT LABORATORIES (US) 2013-04-16 US disclosed
US-20120322734-A1 Pharmaceutical Compositions Including Low Dosages of Desmopressin SERENITY PHARMACEUTICALS LLC 2012-12-20 US disclosed
US-7799761-B2 Pharmaceutical compositions including low dosages of desmopressin ALLERGAN, INC. (US) 2010-09-21 US disclosed
US-20100222346-A1 4-BENZYLAMINOQUINOLINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY ABBVIE DEUTSCHLAND GMBH & CO KG (DE) 2010-09-02 US disclosed
US-20100222346-A1 4-BENZYLAMINOQUINOLINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY ABBVIE DEUTSCHLAND GMBH & CO KG (DE) 2010-09-02 US disclosed
EP-2178842-A2 4-BENZYLAMINOQUINOLINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE Abbott GmbH & Co. KG (DE) 2010-04-28 EP disclosed
US-20100056436-A1 Pharmaceutical Compositions Including Low Dosages of Desmopressin SERENITY PHARMACEUTICALS LLC 2010-03-04 US disclosed
US-7579321-B2 Pharmaceutical compositions including low dosages of desmopressin REPRISE BIOPHARMACEUTICS, LLC (US) 2009-08-25 US disclosed
WO-2009024611-A2 4-BENZYLAMINOQUINOLINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE ABBOTT GMBH & CO. KG (DE) 2009-02-26 WO disclosed
WO-2009024611-A2 4-BENZYLAMINOQUINOLINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE ABBOTT GMBH & CO. KG (DE) 2009-02-26 WO disclosed
US-20090005432-A1 PHARMACEUTICAL COMPOSITIONS INCLUDING LOW DOSAGES OF DESMOPRESSIN SERENITY PHARMACEUTICALS LLC 2009-01-01 US disclosed
US-20080274951-A1 PHARMACEUTICAL COMPOSITIONS INCLUDING LOW DOSAGES OF DESMOPRESSIN FIRST GENERATION CAPITAL INC. (CA) 2008-11-06 US disclosed
US-7405203-B2 Pharmaceutical compositions including low dosages of desmopressin REPRISE BIOPHARMACEUTICS, LLC (US) 2008-07-29 US disclosed
US-20070265207-A1 Pharmaceutical Compositions Including Low Dosages of Desmopressin Acerus Pharmaceuticals USA, LLC 2007-11-15 US disclosed
US-20040138098-A1 Pharmaceutical compositions including low dosages of desmopressin FIRST GENERATION CAPITAL INC. (CA) 2004-07-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100222346-A1 4-BENZYLAMINOQUINOLINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY GDI2, GDI1, NQO2 MEN1 1704/4885KMT2A 1738/4885GPR35 727/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.